0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Other Articles |

Factors Predicting Outcome in Malignant Minor Salivary Gland Tumors of the Oropharynx

N. Gopalakrishna Iyer, MD, PhD, FRCS; Leslie Kim, MD; Iain J. Nixon, MD; Frank Palmer, BA; Dennis Kraus, MD; Ashok R. Shaha, MD; Jatin P. Shah, MD, PhD; Snehal G. Patel, MD; Ian Ganly, MD, PhD, FRCS
Arch Otolaryngol Head Neck Surg. 2010;136(12):1240-1247. doi:10.1001/archoto.2010.213.
Text Size: A A A
Published online

ABSTRACT

Objectives  To report our experience in the care of patients with minor salivary gland cancers occurring only in the oropharynx and to determine factors predictive of outcome.

Design  Retrospective analysis.

Setting  Memorial Sloan-Kettering Cancer Center.

Patients  Sixty-seven patients with malignant minor salivary gland tumors were identified from a preexisting database of patients with cancers of the oropharynx between January 1985 and December 2005.

Main Outcome Measures  Overall survival, disease-specific survival, and recurrence-free survival were calculated by the Kaplan-Meier method. Factors predictive of outcome were identified by univariate and multivariate analyses.

Results  The most common histologic types were mucoepidermoid carcinoma in 26 patients (39%), adenoid cystic carcinoma in 16 (24%), adenocarcinoma in 16 (24%), and malignant mixed tumor in 7 (10%). The tumors were located in the base of the tongue in 41 patients (61%), soft palate in 20 (30%), and tonsil in 6 (9%). With a median follow-up time of 86 months (range, 12-249 months), overall outcomes at 5 and 10 years were overall survival, 80% and 53%; disease-specific survival, 87% and 67%; and recurrence-free survival, 69% and 60%, respectively. Tumor recurred in 20 patients (34%); 12 of these patients had locoregional failure and 15 developed distant metastases. Multivariate analyses showed that clinical T stage, anatomic subsite, and margin status were independent predictors for overall survival; T stage and margin status were independent predictors for locoregional recurrence-free survival.

Conclusion  Clinical T stage, anatomic subsite, and margin status are independent predictors of outcome of patients with minor salivary gland cancers of the oropharynx.

Figures in this Article

Topics

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Figures

Place holder to copy figure label and caption
Figure 1.

Overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) for entire cohort.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Overall survival (OS) and distant recurrence-free survival (DRFS) for mucoepidermoid carcinoma (MEC) vs adenoid cystic carcinoma (ACC).

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Overall survival for polymorphous low-grade adenocarcinoma (PLGA) vs adenocarcinoma, not otherwise specified.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Regional recurrence-free survival (RRFS) by stratified by grade for mucoepidermoid carcinoma.

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

338 Views
18 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();